Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bionano Genomics, Inc.BNGO · Entity 7831 | General Counsel | August 03, 2026 | August 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bionano Genomics, Inc.
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.12 · Expires 2036-08-02 | Direct | 15,000 |
Reported balance
After 2026-08-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-03 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares subject to the option vest 50% of the total on each of the first and second anniversaries of the vesting commencement date, in each case subject to the Reporting Person's Continuous Service (as defined in the Company's 2018 Plan) through each applicable vesting date. F2: The initial Form 3 filed on August 5, 2026 was erroneously filed. This Form 4 replaces the Form 3 filed. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest 50% of the total on each of the first and second anniversaries of the vesting commencement date, in each case subject to the Reporting Person's Continuous Service (as defined in the Company's 2018 Plan) through each applicable vesting date.
F2: The initial Form 3 filed on August 5, 2026 was erroneously filed. This Form 4 replaces the Form 3 filed.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 5, 2026 21:27 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001967837-26-000010 · ownership.xml · derivative · entry 1 Dixon Jonathan V. · CIK 0001967837 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-08-02 F1 · derivative.exercise_date: The shares subject to the option vest 50% of the total on each of the first and second anniversaries of the vesting commencement date, in each case subject to the Reporting Person's Continuous Service (as defined in the Company's 2018 Plan) through each applicable vesting date. F2 · balance_after: The initial Form 3 filed on August 5, 2026 was erroneously filed. This Form 4 replaces the Form 3 filed. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 00:52 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 24 | $1.30 | $31.20 |
DisclosureSEC source: 0001967837-26-000006 · ownership.xml · nonDerivative · entry 1 Dixon Jonathan V. · CIK 0001967837 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 24 shares of common stock in connection with shares that vested on June 3, 2026, pursuant to an RSU award granted on June 3, 2024, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F1 · shares: The reporting person is reporting the withholding by the Issuer of an aggregate of 24 shares of common stock in connection with shares that vested on June 3, 2026, pursuant to an RSU award granted on June 3, 2024, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 21:28 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 6 | $1.10 | $6.60 |
DisclosureSEC source: 0001967837-26-000004 · ownership.xml · nonDerivative · entry 1 Dixon Jonathan V. · CIK 0001967837 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 263 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 6 shares of common stock in connection with shares that vested on February 15, 2026 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:16 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 26,117 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001967837-26-000002 · ownership.xml · derivative · entry 1 Dixon Jonathan V. · CIK 0001967837 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,117 Underlying: Common Stock · 26,117 shares Expires 2036-02-01 F1 · derivative.exercise_date: Each option award vests as follows: the shares subject to the option vest monthly over 48 months beginning on the one-month anniversary of the vesting commencement date, such that the option shall be fully vested and exercisable on the four-year anniversary of the vesting commencement date. Read SEC document |
| June 03, 2025 Filed Jun 3, 2025 22:58 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 25 | $3.69 | $92.25 |
DisclosureSEC source: 0001411690-25-000052 · wk-form4_1748991495.xml · nonDerivative · entry 1 Dixon Jonathan V. · CIK 0001967837 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 25 shares of common stock in connection with shares that vested on June 3, 2025, pursuant to an RSU award granted on June 3, 2024, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F1 · shares: The reporting person is reporting the withholding by the Issuer of an aggregate of 25 shares of common stock in connection with shares that vested on June 3, 2025, pursuant to an RSU award granted on June 3, 2024, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 22:45 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 6,559 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001411690-25-000030 · wk-form4_1742337949.xml · derivative · entry 1 Dixon Jonathan V. · CIK 0001967837 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,559 Underlying: Common Stock · 6,559 shares Expires 0035-03-13 F1 · derivative.exercise_date: Each option award vests as follows: the shares subject to the option vest monthly over 48 months beginning on the one-month anniversary of the vesting commencement date, such that the option shall be fully vested and exercisable on the four-year anniversary of the vesting commencement date. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 23:57 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 6 | $5.73 | $34.38 |
DisclosureSEC source: 0001411690-25-000018 · wk-form4_1740009420.xml · nonDerivative · entry 1 Dixon Jonathan V. · CIK 0001967837 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 294 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 6 shares of common stock in connection with shares that vested on February 15, 2025 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F1 · shares: The reporting person is reporting the withholding by the Issuer of an aggregate of 6 shares of common stock in connection with shares that vested on February 15, 2025 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F2 · balance_after: On January 24, 2025, the common stock of Bionano Genomics, Inc. split 1-for-60, resulting in the reporting person's ownership of 17,725 less shares of common stock. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 21:42 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 68,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001415889-24-015620 · form4-06052024_090600.xml · derivative · entry 2 Dixon Jonathan V. · CIK 0001967837 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,000 Underlying: Common Stock · 68,000 shares Expires 2034-06-02 F3 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of June 3, 2024 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 21:42 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantCommon Stock | 14,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015620 · form4-06052024_090600.xml · nonDerivative · entry 1 Dixon Jonathan V. · CIK 0001967837 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,025 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan. F2 · shares: The shares subject to the RSUs vest 1/4th annually beginning on the one-year anniversary of the grant date. Read SEC document |
| February 15, 2024 Filed Mar 5, 2024 22:44 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 402 | $1.27 | $510.54 |
DisclosureSEC source: 0001415889-24-006808 · form4-03052024_100330.xml · nonDerivative · entry 1 Dixon Jonathan V. · CIK 0001967837 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,525 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 402 shares of common stock in connection with shares that vested on February 15, 2024 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F1 · shares: The reporting person is reporting the withholding by the Issuer of an aggregate of 402 shares of common stock in connection with shares that vested on February 15, 2024 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F2 · balance_after: On August 4, 2023, the common stock of Bionano Genomics, Inc. split 1-for-10, resulting in the reporting person's ownership of 35,343 less shares of common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.